BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.44%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$553M
AUM Growth
+$553M
(+4.1%)
Cap. Flow
-$6.09M
Cap. Flow
% of AUM
-1.1%
Top 10 Holdings %
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10
Top Buys
| 1 |
Viatris
VTRS
|
$4.42M |
| 2 |
Ligand Pharmaceuticals
LGND
|
$3.66M |
| 3 |
AKRX
Akorn, Inc.
AKRX
|
$3.41M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$3.22M |
| 5 |
ENDP
Endo International plc
ENDP
|
$2.78M |
Top Sells
| 1 |
CVS Health
CVS
|
$6.24M |
| 2 |
Cardinal Health
CAH
|
$5.79M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
$4.7M |
| 4 |
STJ
St Jude Medical
STJ
|
$4.68M |
| 5 |
Humana
HUM
|
$3.4M |
Sector Composition
| 1 | Healthcare | 92.11% |
| 2 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$119B
| $21.4M | 3.86% | 247,500 -35,000 | -12% | -$3.02M |
|
2
Stryker
SYK
$150B
| $21M | 3.8% | 180,800 +3,800 | +2% | +$442K |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $20.3M | 3.67% | 194,250 -1,800 | -0.9% | -$188K |
|
4
Illumina
ILMN
$15.8B
| $17.2M | 3.1% | 94,475 +2,900 | +3% | +$527K |
|
5
Biogen
BIIB
$19.4B
| $17.1M | 3.08% | 54,500 | – | – |
|
6
Abbott
ABT
$231B
| $16.2M | 2.93% | 384,000 +2,500 | +0.7% | +$106K |
|
|
7
Regeneron Pharmaceuticals
REGN
$61.5B
| $15.3M | 2.76% | 38,000 +8,000 | +27% | +$3.22M |
|
8
Amgen
AMGN
$155B
| $13.9M | 2.52% | 83,500 | – | – |
|
9
UnitedHealth
UNH
$281B
| $13.9M | 2.51% | 99,200 | – | – |
|
10
Boston Scientific
BSX
$156B
| $13.7M | 2.47% | 575,000 +75,000 | +15% | +$1.79M |
|
11
Gilead Sciences
GILD
$140B
| $12.4M | 2.24% | 156,500 | – | – |
|
|
12
Ligand Pharmaceuticals
LGND
$3.15B
| $10.9M | 1.97% | 106,880 +35,850 | +50% | +$3.66M |
|
13
Zimmer Biomet
ZBH
$21B
| $10.4M | 1.88% | 80,000 -6,200 | -7% | -$806K |
|
14
Edwards Lifesciences
EW
$47.8B
| $10.2M | 1.85% | 85,000 +17,000 | +25% | +$2.05M |
|
15
Jazz Pharmaceuticals
JAZZ
$7.75B
| $10.2M | 1.84% | 83,800 +8,500 | +11% | +$1.03M |
|
16
Becton Dickinson
BDX
$55.3B
| $9.89M | 1.79% | 55,000 -4,000 | -7% | -$719K |
|
17
Centene
CNC
$14.3B
| $9.47M | 1.71% | 141,430 +24,050 | +20% | +$1.61M |
|
18
Hologic
HOLX
$14.9B
| $9.4M | 1.7% | 242,100 +3,800 | +2% | +$148K |
|
19
Baxter International
BAX
$12.7B
| $9.04M | 1.63% | 190,000 +24,000 | +14% | +$1.14M |
|
|
20
Viatris
VTRS
$12.3B
| $8.99M | 1.62% | 235,700 +116,000 | +97% | +$4.42M |
|
|
21
Cardinal Health
CAH
$35.5B
| $8.88M | 1.6% | 114,280 -74,500 | -39% | -$5.79M |
|
22
Intuitive Surgical
ISRG
$170B
| $8.7M | 1.57% | 12,000 | – | – |
|
23
Teva Pharmaceuticals
TEVA
$21.1B
| $8.61M | 1.56% | 187,190 -42,000 | -18% | -$1.93M |
|
24
Incyte
INCY
$16.5B
| $8.58M | 1.55% | 91,000 | – | – |
|
25
Cigna
CI
$80.3B
| $7.78M | 1.41% | 59,722 +11,722 | +24% | +$1.53M |
|